



MEDIA STATEMENT

17 FEBRUARY, 2005

**CSL AND BAYER HEALTHCARE AGREEMENT TO PROVIDE
RECOMBINANT FACTOR VIII FOR AUSTRALIANS LIVING
WITH HAEMOPHILIA A**

CSL Limited, Australia's national fractionator of plasma therapeutics since 1952, and Bayer HealthCare - Australia, today announced an agreement, with an initial 5 year term, granting CSL Limited's Bioplasma Division exclusive distribution rights to KOGENATE[®]FS in Australia. KOGENATE[®]FS is a leading recombinant Factor VIII used in the treatment of Haemophilia A, and manufactured using advanced recombinant DNA technology.

'With the addition of KOGENATE[®]FS, CSL Bioplasma is able to offer an expanded range of trusted products to people living with Haemophilia A. CSL Bioplasma will now provide KOGENATE[®]FS - a leading recombinant Factor VIII, in addition to BIOSTATE[®] - a world-class plasma-derived Factor VIII fractionated from plasma donated by Australians.' Mr Paul Bordonaro, General Manager of CSL's Bioplasma Division said today.

'This collaboration will combine the innovation of Bayer HealthCare with CSL Bioplasma's comprehensive distribution and on the ground customer support capability in Australia, and ensure Australians have long term access to KOGENATE[®]FS' said Mr Bordonaro.

Australia Bayer HealthCare Managing Director Mr Derrill Palidwar commented:
"This collaboration has been designed to ensure there will be product choice available for Australians. The combined expertise of both companies in Australia will provide a higher level of service and support to the haemophilia community."

Further information:

CSL Limited:

Mark Dehring (Financial Media enquiries) 03 9389 2818
Dr Rachel David (General and Medical Media enquiries) 03 9389 1821

Bayer Healthcare – Australia:

Kirsten Impey (Bayer Communications Manager) 02 9391 6077
Derrill Palidwar (Bayer HealthCare Managing Director) 02 9391 6077

[®] KOGENATE FS is a registered trade mark of Bayer AG, BIOSTATE is a registered trade mark of CSL Limited.